You’ve probably seen the clinical trial data backing WeightWatchers and Jenny Craig, but here’s the problem: both companies went bankrupt, and the programs researchers actually tested no longer exist. So what evidence are you really relying on when choosing between them in 2026?
Key Takeaways
- Both WeightWatchers and Jenny Craig went bankrupt – but in very different ways, leaving behind two fundamentally different programs than the ones clinical trials actually tested.
- Jenny Craig’s landmark JAMA evidence was built on in-person counselors and physical centers that no longer exist anywhere; applying that data to today’s mail-order meal service is not scientifically valid.
- GLP-1 medications like Wegovy and Zepbound produce 15-20% body weight loss on average – far exceeding the 3-8% typical of behavioral programs like WeightWatchers or Jenny Craig.
- WeightWatchers emerged from Chapter 11 in June 2025 as a private company and is now pivoting hard toward GLP-1 telehealth, with clinical revenue up 57% year-over-year in Q1 2025, making its older behavioral trial data only part of the story.
- Choosing between these programs today requires understanding what each company actually sells in 2026 – not what researchers studied a decade ago.
If the science behind a weight loss program no longer matches what the program actually does, the science stops being a good reason to choose it. That’s the quiet problem at the center of the Weight Watchers vs. Jenny Craig debate in 2026.
The Science You’re Relying On No Longer Matches the Programs Being Sold
Most comparisons of WeightWatchers and Jenny Craig cite the same cluster of peer-reviewed trials – a 2011 Lancet RCT for WW, a 2010 JAMA RCT for Jenny Craig. These are legitimate studies. But the programs those researchers tested have since been reshaped, gutted, or sold off entirely. Citing them to make a 2026 purchasing decision is a bit like reading a review of a restaurant that closed two years ago and was replaced by a completely different concept under the same sign.
For consumers who take evidence seriously – the kind who actually look up clinical trials before spending $600 a month – this distinction matters enormously. Weight Loss Mindset covers this exact gap between marketed science and lived reality at weightlossmindset.co, and the Weight Watchers vs. Jenny Craig comparison is one of the clearest examples of why that gap exists.
Two Bankruptcies, Two Very Different Outcomes
The word bankruptcy gets used loosely, but the legal type tells the whole story here. WeightWatchers and Jenny Craig filed under completely different chapters of the bankruptcy code – and that difference determines whether either program still exists in a meaningful sense.
Jenny Craig: Full Liquidation, Brand Sold to Nutrisystem’s Parent
Jenny Craig filed Chapter 7 in Delaware on May 5, 2023 – full liquidation, not restructuring. All roughly 500 physical centers across the US and Canada shut down immediately. Around 1,000 US employees were let go. The brand and intellectual property were purchased by Wellful Inc. – the parent company of Nutrisystem – for up to $10 million per court filings. By fall 2023, a relaunched JennyCraig.com was selling meal delivery plans online. No centers reopened. No in-person counselors returned.
WeightWatchers: Chapter 11, Emerged Private with a GLP-1 Telehealth Arm
WeightWatchers filed Chapter 11 – reorganization, not liquidation – on May 6, 2025. Per law firm Simpson Thacher, the court-approved plan reduced WeightWatchers’ debt by approximately $1.15 billion, more than 70% of its roughly $1.6 billion load, leaving about $475 million outstanding. The company was delisted from Nasdaq, then emerged as a private company on June 24, 2025. It remains operational. Its forward strategy now centers on the WW Clinic, which prescribes brand-name GLP-1 medications and layers behavioral support on top, with clinical revenue up 57% year-over-year in Q1 2025.
Same word, completely different outcomes. One company restructured and pivoted. The other ceased to exist operationally and was reborn as something different under new ownership.
The Clinical Trials Tested Programs That No Longer Exist
This is the core problem with relying on older research to choose between these programs today.
Jenny Craig’s JAMA Evidence Was Built on In-Person Counselors
The flagship Jenny Craig trial – Rock et al., published in JAMA in 2010 and funded by Jenny Craig – found that center-based clients lost 10.1 kg at 12 months and maintained 7.4 kg (7.9% of initial weight) at 24 months, compared to just 2.0 kg for usual care. Those are genuinely impressive numbers. But that study tested weekly, in-person, one-on-one counselor meetings inside physical Jenny Craig centers, with food provided free to participants. Every one of those structural elements is gone. The 2026 Jenny Craig is a direct-to-consumer meal delivery website owned by the same private equity-backed company that runs Nutrisystem. Applying the Rock 2010 data to that service is not scientifically valid – a point that gets consistently underplayed in consumer comparisons.
WeightWatchers’ Lancet Trials Predate Its GLP-1 Integration
WeightWatchers’ clinical evidence is stronger in one sense – the company still exists under the same name and still offers behavioral programming. The Jebb 2011 Lancet RCT (772 adults, WW-funded) found a 12-month weight difference of -2.77 kg in favor of WeightWatchers over standard care. The WRAP trial (Ahern 2017, Lancet) confirmed a dose-response effect: 52 weeks of WW produced more loss than 12 weeks. But the 5-year WRAP follow-up, published in Lancet Public Health in 2022, showed near-total regain – no statistically significant between-group differences remained at year five. None of those trials involved GLP-1 prescriptions, telehealth clinicians, or the WW Clinic model that now defines the company’s growth strategy. The behavioral evidence and the medication evidence are measuring different products.
GLP-1 Drugs Broke the Old Comparison Entirely
15-20% vs. 3-8%: Why Medication Outpaces Both Programs
To understand why both companies collapsed when they did, it helps to look at what entered the market. Tirzepatide (Zepbound/Mounjaro) produced approximately 20-22.5% body weight loss in the SURMOUNT-1 trial at 72 weeks. Semaglutide (Wegovy) produces roughly 15% on average. Behavioral-only programs like traditional WeightWatchers or Jenny Craig typically produce 3-8%. That is not a marginal gap – it’s a different category of result entirely.
J.P. Morgan Research estimates approximately 25 million Americans will be on GLP-1 treatment by 2030, up from around 10 million in 2025. That’s the market force that drove Jenny Craig into liquidation and pushed WeightWatchers into Chapter 11. WeightWatchers is now betting its survival on being the behavioral wrapper around GLP-1 prescriptions – not on its Points system alone. Its own data claims GLP-1 users with structured behavioral support lose more weight than medication alone, though that claim comes from the company itself.
What the Evidence Actually Shows on Cost and Efficacy
WeightWatchers Has Been the Lower-Cost Option; Jenny Craig Runs $600-$800/Month
Cost-effectiveness research from Finkelstein and Kruger (Obesity, 2014) found WeightWatchers to be the most cost-effective commercial weight loss program studied, at approximately $155 per kilogram lost, compared to roughly $338+ per kilogram for Jenny Craig. That gap has only widened since then.
- WeightWatchers (2026): Core digital plan runs approximately $12/month on an annual plan. The workshop tier typically starts around $45/month, though promotional rates can be lower, sometimes around $19-$22/month for longer commitments. The WW Clinic GLP-1 track runs $74/month – medication costs are separate and typically $349-$499/month for brand-name GLP-1s, though insurance can reduce this significantly.
- Jenny Craig (2026): Meal plans run approximately $20-$28/day depending on the plan, roughly $600-$800/month. Shipping is free for 2-week auto-ship plan orders within the contiguous US, but can run around $15-$29 for other orders or higher for Canadian provinces.
For context: Nutrisystem, owned by the same parent company as the relaunched Jenny Craig, offers a functionally similar meal delivery product for roughly $100-$200/month less.
Both Programs Face the Long-Term Weight Maintenance Challenge
The WRAP 5-year data make this uncomfortable but important: by year five, the weight loss advantage of WeightWatchers over the control group was no longer statistically significant. While Jenny Craig’s landmark JAMA trial showed weight maintenance at 24 months, broader research on behavioral weight loss programs indicates that most participants regain the majority of lost weight within 2-5 years after stopping the program, a trend also observed in WeightWatchers’ 5-year WRAP trial. This reflects how weight regain works biologically, but it’s critical context for any consumer expecting lasting results from a behavioral program alone.
Today’s Jenny Craig Is Meal Delivery – Not a Clinical Program
The 2026 Jenny Craig sells three meal plans – the Simple Meal Plan, the Essential Plan, and the Max Up plan – delivered to your door, with virtual coaching available. Operationally, it is indistinguishable from other direct-to-consumer meal delivery services in the weight management space. The company has even launched a GLP-1 companion meal line, acknowledging that many of its customers are already on medication. What it does not offer is in-person counselors, physical centers, or any resemblance to the model that produced its peer-reviewed results. Shipping is limited to the contiguous US and select Canadian provinces.
Prepackaged, portion-controlled meals can support weight loss when used consistently. The problem arises when consumers assume the JAMA trial outcomes transfer to this version of the program. They don’t.
Match Your Choice to the Program That Actually Exists Today
Given all of the above, here’s how to think clearly about which option makes sense in 2026:
- If cost and evidence matter most: WeightWatchers is the lower-cost, more cost-effective option with the stronger – if imperfect – evidence base for its behavioral model. Commit to at least 52 weeks; the WRAP trial showed a clear dose-response effect with duration.
- If convenient, structured meal delivery appeals to you and budget allows: The relaunched Jenny Craig can support weight loss, but understand it’s a meal delivery service with virtual coaching – not a clinical program. Nutrisystem, from the same parent company, offers a nearly identical product at a meaningfully lower price point.
- If maximum results are the goal and a BMI of 30+ (or 27+ with a comorbidity) applies: GLP-1 medications far exceed what either behavioral program can achieve on its own. WeightWatchers’ WW Clinic or a comparable telehealth platform can bundle prescribing with behavioral support – which WW’s own data suggests improves outcomes over medication alone.
One practical benchmark worth watching: if the relaunched Jenny Craig publishes peer-reviewed outcome data on its current online-only model, or matches Nutrisystem’s pricing, the calculus shifts. Until then, the old JAMA numbers don’t apply to what’s being sold today.
For evidence-grounded guidance on weight loss decisions beyond the marketing, Weight Loss Mindset helps health-conscious consumers cut through the noise and make choices based on what the science actually says.
